Business DevelopmentMNC China Lens
A KRAS-EGFR Dual-Targeting ATTC Drug Goes Global! HUTCHMED and GSK Reach a Worldwide License Agreement
On September 3, 2026, HUTCHMED announced a worldwide license agreement with GSK for HMPL-A830, its first-in-class KRAS-EGFR dual-targeting antibody-targeted conjugate (ATTC), granting GSK exclusive development and commercialization rights outside Greater China. The drug pairs an anti-EGFR antibody with a KRAS inhibitor payload to dually block signaling pathways, aiming to improve efficacy and tolerability in KRAS-mutant colorectal, pancreatic, and lung cancers. HUTCHMED will receive a USD 110 million upfront payment plus up to USD 1.185 billion in milestones and royalties, retaining Greater China rights; GSK also secured priority negotiation rights for another early-stage ATTC. A global Phase I study led by HUTCHMED is expected in H2 2026, with GSK leading overseas development and commercialization — a milestone for precision oncology addressing unmet need for safe, durable regimens.
2min read
Read More
Finance
Innovation
Startups
Medical Device Approved
IPO
Ranking
Business Development
Data
VIEW ALL
Innovation
China's First Super-Microsurgery Robot 'Dishi Lingfeng' Successfully Completes First Patient Enrollment in Registered Clinical Trial for Lymphedema Treatment
On September 2, 2026, the domestically developed 'Dishi Lingfeng' microsurgical robot, created by Hangzhou Dessight Biomedical Co. Ltd., successfully completed its first patient enrollment in a registered clinical trial for robotic-assisted lymphaticovenular anastomosis (LVA) at Zhejiang Provincial People's Hospital. Led by Professor Zheng Youmao, the procedure marked China's first registered clinical trial using a surgical robot for super-microsurgery to treat secondary lymphedema. The Dishi Lingfeng system overcomes the limitations of human dexterity with real-time tremor filtering, motion scaling, and micro-wristed instruments capable of micron-level precision, enabling the connection of lymphatic vessels as small as 0.1 to 1 millimeter in diameter. This multi-center trial will generate rigorous clinical evidence to support regulatory approval and demonstrate the safety and effectiveness of robotic-assisted super-microsurgery for lymphedema patients.
3min read
Read More
Innovation
Industry News: AbbVie's Bispecific Antibody Hits Dual Primary Endpoints in Phase 3; GLP-1 Therapy Licensed for Up to €726M; HUTCHMED Inks $1.295B Deal with GSK
This industry news roundup highlights three major pharmaceutical developments: 1) AbbVie's investigational bispecific antibody etentamig achieved positive topline results in the Phase 3 CERVINO trial, meeting dual primary endpoints for relapsed/refractory multiple myeloma; 2) Gan & Lee Pharmaceuticals and Menarini Group reached an exclusive licensing agreement for the long-acting GLP-1 therapy bofanglutide, with a total potential deal value of up to €726 million; and 3) HUTCHMED entered an exclusive licensing agreement with a GSK subsidiary for the KRAS-EGFR antibody-targeted conjugate HMPL-A830, with a total potential deal value of up to $1.295 billion.
3min read
Read More
InnovationMNC China Lens
Medtronic Invests ~$700M in Cornerstone Robotics; Akeso's Ivonescimab HARMONi-2 OS Interim Analysis Positive
Medtronic has announced a strategic investment of approximately $700 million in Chinese surgical-robotics startup Cornerstone Robotics (Kangnuositeng) and secured distribution rights for its Sentire laparoscopic surgical robot in markets outside the U.S. In oncology news, Akeso reported that an interim analysis of overall survival (OS) in its Phase III HARMONi-2 study met the key secondary endpoint with statistical significance. The trial evaluates Akeso's PD-1/VEGF bispecific antibody ivonescimab against pembrolizumab as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC).
5min read
Read More
Innovation
ApicHope's Innovative Gout Drug AR882 Meets Primary Endpoint in Phase III Trial
ApicHope Pharmaceutical Group Co., Ltd. announced that its innovative drug AR882 has successfully met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia. This significant milestone positions AR882 as a potential breakthrough therapy for millions of patients facing limited treatment options. The company plans to leverage these positive results to advance discussions with China's National Medical Products Administration for potential marketing authorization.
1min read
Read More
Business Development
Biocytogen Grants Qilu Pharmaceutical Non-Exclusive License for Fully Human Nanobody Molecule to Support Neuroscience Drug Development
Biocytogen Pharmaceuticals has signed a non-exclusive license agreement with Qilu Pharmaceutical, granting rights to a single fully human nanobody molecule generated via its proprietary RenNano® platform for use in neuroscience drug development. The deal includes an upfront payment and additional milestone-based payments tied to development, regulatory, and commercialization achievements. Qilu Pharmaceutical will integrate the molecule into its R&D pipeline to explore innovative treatments for nervous system diseases, leveraging Biocytogen's nanobody technology to address the high scientific and translational challenges in neuroscience drug R&D.
3min read
Read More
Innovation
Betta Pharmaceuticals' Ensartinib Wins NMPA Approval for Post-Surgical Adjuvant Treatment in ALK-Positive NSCLC, Achieving 86.4% Two-Year Disease-Free Survival Rate
Betta Pharmaceuticals has received approval from China's NMPA for ensartinib hydrochloride capsules as a post-surgical adjuvant treatment for ALK-positive Stage IB to IIIB non-small cell lung cancer (NSCLC), marking the drug's third approved indication. Clinical data demonstrated a two-year disease-free survival rate of 86.4% and an 80% reduction in disease recurrence risk compared to the control group. This approval expands treatment options for early-stage ALK-positive NSCLC patients, a subtype that accounts for 3% to 5% of all NSCLC cases and predominantly affects younger patients with less smoking history.
1min read
Read More

Finance

VIEW ALL
Time
Company Name
Brief Introduction
Area
Funding rounds
Amount
No data available

Business Development

VIEW ALL
Transaction Type
Transaction Date
Transferor (Seller)
Transferee (Buyer)
Trading products
Clinical Stage
Amount
Source
No data available

Product Approved

VIEW ALL
Company Name
Product
Product Details
Product Type
Approval Authority
Document Types
Approval time
No data available